Basic Stats
| LEI | 529900Z84WFDHPS3JP76 |
| CIK | 1419041 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Forte Biosciences, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 14, 2025 |
EX-99.2 Exhibit 99.2 FORTE BIOSCIENCES FORTE BIOSCIENCES AUGUST 2025 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, kno |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2025 |
EX-99.1 Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES UPDATE Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata DALLAS, TX – AUGUST 14, 2025 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-r |
|
| June 25, 2025 |
FORTE BIOSCIENCES ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING Exhibit 99.1 FORTE BIOSCIENCES ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING DALLAS, TX – JUNE 24, 2025 – Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of com |
|
| June 25, 2025 |
Underwriting Agreement, dated as of June 24, 2025. Exhibit 1.1 5,630,450 Shares of Common Stock Pre-Funded Warrants to Purchase up to 619,606 Shares of Common Stock Forte Biosciences, Inc. UNDERWRITING AGREEMENT June 24, 2025 TD SECURITIES (USA) LLC EVERCORE GROUP L.L.C. GUGGENHEIM SECURITIES, LLC CHARDAN CAPITAL MARKETS, LLC AS REPRESENTATIVES OF THE SEVERAL UNDERWRITERS C/O TD SECURITIES (USA) LLC 1 VANDERBILT AVENUE NEW YORK, NEW YORK 10017 C/O |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 25, 2025 |
5,630,450 Shares of Common Stock Pre-Funded Warrants to Purchase 619,606 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286226 PROSPECTUS SUPPLEMENT (To Prospectus dated April 3, 2025) 5,630,450 Shares of Common Stock and Pre-Funded Warrants to Purchase 619,606 Shares of Common Stock We are offering 5,630,450 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and accompanying prospectus and, in lieu o |
|
| June 25, 2025 |
Exhibit 4.1 FORTE BIOSCIENCES, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2025 Forte Biosciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns ( |
|
| June 24, 2025 |
SUBJECT TO COMPLETION, DATED JUNE 24, 2025 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286226 This preliminary prospectus supplement and accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanyin |
|
| June 23, 2025 |
Exhibit 99.1 FORTE BIOSCIENCES ANNOUNCES POSITIVE DATA IN FB102 CELIAC DISEASE PHASE 1B STUDY Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET DALLAS, TX – JUNE 23, 2025 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimm |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 23, 2025 |
Exhibit 99.2 FORTE BIOSCIENCES FB102 CELIAC DISEASE PHASE 1B RESULTS JUNE 2025 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of |
|
| June 23, 2025 |
Exhibit 99.3 FORTE BIOSCIENCES FORTE BIOSCIENCES JUNE 2025 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2025 |
FORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES UPDATE EX-99.1 Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES UPDATE DALLAS, TX – MAY 15, 2025 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2025 financial results and provided a clinical update. “We are looking forward to reading out th |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| May 15, 2025 |
Amended and Restated 2021 Equity Incentive Plan and forms of agreements thereunder. FORTE BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options, Nonstatut |
|
| May 15, 2025 |
Exhibit 10.4 LETTER AGREEMENT THIS LETTER AGREEMENT (this “Agreement”), dated as of November 21, 2024, is by and between Forte Biosciences, Inc., a Delaware corporation (the “Company”) and Tybourne Strategic Opportunities Fund II, LP (the “Purchaser”). WHEREAS, the Company and the Purchaser are parties to that certain Securities Purchase Agreement dated as of November 19, 2024 (the “Purchase Agree |
|
| May 15, 2025 |
Amended and Restated Non-Employee Director Compensation Policy. Forte Biosciences, Inc. Amended and Restated Non-Employee Director Compensation Policy (March 20, 2025) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Forte Biosciences, Inc. (“Forte Biosciences”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated |
|
| May 15, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2025 |
Exhibit 10.3 LETTER AGREEMENT THIS LETTER AGREEMENT (this “Agreement”), dated as of November 21, 2024, is by and among Forte Biosciences, Inc., a Delaware corporation (the “Company”) and OrbiMed Private Investments IX, LP, OrbiMed Genesis Master Fund, L.P., The Biotech Growth Trust PLC (together, “OrbiMed”). WHEREAS, the Company and OrbiMed are parties to that certain Securities Purchase Agreement |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 4, 2025 |
FORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES CLINICAL UPDATE Exhibit 99 FORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES CLINICAL UPDATE DALLAS, TX – MARCH 31, 2025 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update. “2024 was a very productive year with significant progress |
|
| April 4, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 1, 2025 |
CORRESP April 1, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Daniel Crawford Re: Forte Biosciences, Inc. Registration Statement on Form S-3 File No. 333-286226 Acceleration Request Requested Date: April 3, 2025 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant |
|
| March 28, 2025 |
Exhibit 4.3 FORTE BIOSCIENCES, INC. INDENTURE Dated as of , 20 Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 3 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE II THE SECURITIES 4 Section 2.1 Issuable in Series 4 Section 2.2 Establishment of Ter |
|
| March 28, 2025 |
Exhibit 21.1 Subsidiaries of Forte Biosciences, Inc.* Name of Subsidiary Jurisdiction of Incorporation or Organization Forte Subsidiary, Inc. Delaware Forte Biosciences Australia Pty Ltd Australia * Inclusion on the list above is not an admission that any of the above entities, individually or in the aggregate, constitutes a significant subsidiary within the meaning of Rule 1-02(w) of Regulation S |
|
| March 28, 2025 |
Exhibit 10.17 Forte Biosciences, Inc. Amended and Restated Non-Employee Director Compensation Policy (March 14, 2024) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Forte Biosciences, Inc. (“Forte Biosciences”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 sep For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38052 FORTE BIOSC |
|
| March 28, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Forte Biosciences, Inc. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
Amended and Restated Insider Trading Policy FORTE BIOSCIENCES, INC. INSIDER TRADING POLICY (As amended and restated on March 23, 2023) A. POLICY OVERVIEW Forte Biosciences, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its o |
|
| March 28, 2025 |
Amended and Restated 2021 Equity Incentive Plan, and forms of agreements thereunder. Exhibit 10.16 FORTE BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Opti |
|
| March 28, 2025 |
Exhibit 97.1 FORTE BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY As adopted on November 9, 2023 Forte Biosciences, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-fo |
|
| February 14, 2025 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G, dated December 31, 2024 (this “Schedule 13G”), with respect to the Common Stock, par value $0. |
|
| February 13, 2025 |
JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) EX-1 2 ex1.htm Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Shares of Forte Biosciences, Inc. together with any or all amendments thereto, when and if required. The parties hereto further consent and agree to file this Joint Filing |
|
| February 10, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EXHIBIT 1 to SCHEDULE 13G JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition st |
|
| February 7, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Forte Biosciences, Inc. |
|
| February 7, 2025 |
As filed with the Securities and Exchange Commission on February 7, 2025 As filed with the Securities and Exchange Commission on February 7, 2025 Registration No. |
|
| January 24, 2025 |
Amended and Restated 2021 Equity Incentive Plan Exhibit 10.1 FORTE BIOSCIENCES, INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN (Adopted and Approved by the Board of Directors on December 30, 2024; approved by the stockholders on January 24, 2025) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Empl |
|
| January 24, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 31, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 20, 2024 |
Forte Biosciences, Inc. 9,546,944 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-283814 PROSPECTUS Forte Biosciences, Inc. 9,546,944 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 9,546,944 shares (the “Shares”) of common stock, par value $0.001 per share, of Forte Biosciences, Inc., a Delaware corporation (the “Company”), by the selling stockholders ident |
|
| December 18, 2024 |
December 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Tim Buchmiller Re: Forte Biosciences, Inc. Registration Statement on Form S-3 File No. 333-283814 Acceleration Request Requested Date: December 20, 2024 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 13, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Forte Biosciences, Inc. |
|
| December 6, 2024 |
FBRX / Forte Biosciences, Inc. / ALGER ASSOCIATES INC - FORTE BIOSCIENCES, INC. Passive Investment SC 13G/A 1 d481112dsc13ga.htm FORTE BIOSCIENCES, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Forte Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G208 (CUSIP Number) November 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| December 3, 2024 |
Exhibit 99.2 FORTE BIOSCIENCES FORTE BIOSCIENCES CORPORATE DECK DEC 3, 2024 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 19 |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 3, 2024 |
Exhibit 99.1 FORTE BIOSCIENCES FORTE BIOSCIENCES DEC 3, 2024 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as th |
|
| November 20, 2024 |
EX-99.1 Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES OVERSUBSCRIBED $53 MILLION PRIVATE PLACEMENT FROM LEADING HEALTHCARE INSTITUTIONAL INVESTORS TO ADVANCE FB102 ACROSS AUTOIMMUNE INDICATIONS DALLAS, TX – November 20, 2024 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announc |
|
| November 20, 2024 |
Securities Purchase Agreement, dated November 19, 2024, by and among the Company and the Purchasers EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG FORTE BIOSCIENCES, INC., AND THE PURCHASERS NOVEMBER 19, 2024 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Common Stock 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 6 3.1 Organization and Power 6 3.2 Capitalization 6 3.3 Registration Rights 7 3.4 Authorization 7 3.5 Valid Is |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 20, 2024 |
EX-4.1 Exhibit 4.1 THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES ARE BEING OFFERED TO INVESTORS WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT IN RELIANCE UPON REGULATION D PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE SECURITIES ACT”). TRANSFER OF THESE SECURITIES AND THE SECURITIES ISSUABLE |
|
| November 20, 2024 |
Registration Rights Agreement, dated November 19, 2024, by and among the Company and the Purchasers EX-10.2 Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of November 19, 2024, by and among Forte Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Com |
|
| November 14, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 14, 2024 |
FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX – NOVEMBER 14, 2024 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update. Third Quarter 2024 Business Hi |
|
| November 14, 2024 |
FBRX / Forte Biosciences, Inc. / ALGER ASSOCIATES INC - FORTE BIOSCIENCES, INC. Passive Investment SC 13G/A 1 d891212dsc13ga.htm FORTE BIOSCIENCES, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Forte Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 14, 2024 |
FBRX / Forte Biosciences, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d912059dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 30, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORTE BIOSCIENCES, INC. Paul A. Wagner. hereby certifies that: ONE: He is the duly elected and acting Chief Executive Officer of Forte Biosciences, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”). TWO: The d |
|
| August 22, 2024 |
Amended and Restated 2021 Equity Incentive Plan. Exhibit 10.1 FORTE BIOSCIENCES, INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of |
|
| August 22, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2024 |
FORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX – AUGUST 14, 2024 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024 results and provided a business update. Second Quarter 2024 Business H |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| August 14, 2024 |
Exhibit 99.2 Exhibit 99.2 FORTE BIOSCIENCES CORPORATE DECK AUGUST 14,2024 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, kn |
|
| July 30, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| July 19, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 17, 2024 |
Termination of Group Agreement, dated June 14, 2024. EX-99.6 2 ex99-6.htm Exhibit 99.6 June 14th, 2024 Re: Termination of Group Agreement, dated August 16, 2023 The undersigned constitute all the parties to that certain Group Agreement dated August 16, 2023 (the “Agreement”). Effective immediately, the undersigned hereby terminate the Agreement in its entirety. [Remainder of this page intentionally left blank; signature pages follow] CAMAC PARTNERS, |
|
| June 17, 2024 |
FBRX / Forte Biosciences, Inc. / Camac Fund, LP Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Amendment No 2. Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSI |
|
| June 14, 2024 |
Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE CAMAC FUND, LP, Plaintiff, v. PAUL A. WAGNER, LAWRENCE EICHENFIELD, BARBARA K. FINCK, DONALD A. WILLIAMS, STEPHEN K. DOBERSTEIN, STEVEN KORNFELD, SCOTT BRUN, and DAVID GRYSKA, Defendants, and FORTE BIOSCIENCES, INC., Nominal Defendant. C.A. No. 2023-0817-MTZ NOTICE OF PENDENCY OF DERIVATIVE AND CLASS ACTION, PROPOSED SETTLEMENT, AND |
|
| June 14, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 14, 2024 |
Exhibit 99.2 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE CAMAC FUND, LP, Plaintiff, v. C.A. No. 2023-0817-MTZ PAUL A. WAGNER, LAWRENCE EICHENFIELD, BARBARA K. FINCK, DONALD A. WILLIAMS, STEPHEN K. DOBERSTEIN, STEVEN KORNFELD, SCOTT BRUN, and DAVID GRYSKA, Defendants, and FORTE BIOSCIENCES, INC., Nominal Defendant. STIPULATION AND AGREEMENT OF SETTLEMENT, COMPROMISE, AND RELEASE This Stipu |
|
| June 14, 2024 |
Exhibit 10.1 Forte Biosciences, Inc. 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 June 11, 2024 Camac Fund, LP c/o Camac Partners, LLC 350 Park Avenue, 13th Floor New York, New York 10022 Ladies and Gentlemen: This standstill and voting agreement (this “Agreement”) constitutes the agreement between (a) Forte Biosciences, Inc. (“Company”) and (b) Camac Fund, LP (“Camac Fund”) and each of |
|
| May 13, 2024 |
FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX – MAY 13, 2024 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlig |
|
| May 13, 2024 |
Exhibit 99.2 FORTE BIOSCIENCES FB-102 OVERVIEW CORPORATE DECK MAY 13, 2024 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 199 |
|
| May 13, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 13, 2024 |
Separation Agreement and Release by and between the Company and Hubert Chen, dated March 17, 2024. Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Hubert Chen (“Executive”) and Forte Biosciences, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive was employed by the Company as its President and Chief Scientific Officer; WHEREAS, Executive s |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| April 29, 2024 |
Powers of Attorney (contained in the signature page to this Annual Report on Form 10-K). Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
|
| April 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Forte Biosciences, Inc. |
|
| April 12, 2024 |
As filed with the Securities and Exchange Commission on April 12, 2024 S-8 As filed with the Securities and Exchange Commission on April 12, 2024 Registration No. |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 18, 2024 |
Amended and Restated 2021 Equity Incentive Plan, and forms of agreements thereunder. Exhibit 10.16 FORTE BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Opti |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 sep For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38052 FORTE BIOSC |
|
| March 18, 2024 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.17 Forte Biosciences, Inc. Amended and Restated Non-Employee Director Compensation Policy (March 14, 2024) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Forte Biosciences, Inc. (“Forte Biosciences”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended |
|
| March 18, 2024 |
FORTE BIOSCIENCES, INC. ANNOUNCES 2023 RESULTS AND PROVIDES BUSINESS UPDATE EX-99.1 Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES 2023 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX – MARCH 18, 2024 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights “Forte achieved a major |
|
| March 18, 2024 |
EX-99.2 Exhibit 99.2 FORTE BIOSCIENCES FB-102 OVERVIEW CORPORATE DECK MARCH 18, 2024 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation |
|
| March 18, 2024 |
Exhibit 21.1 Subsidiaries of Forte Biosciences, Inc.* Name of Subsidiary Jurisdiction of Incorporation or Organization Forte Subsidiary, Inc. Delaware Forte Biosciences Emerald Limited Ireland Forte Biosciences Australia Pty Ltd Australia * Inclusion on the list above is not an admission that any of the above entities, individually or in the aggregate, constitutes a significant subsidiary within t |
|
| March 18, 2024 |
Exhibit 97.1 FORTE BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY As adopted on November 9, 2023 Forte Biosciences, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-fo |
|
| February 16, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Inc |
|
| February 14, 2024 |
EX-99.1 2 exhibit99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of 14 February 2024, is by and among Tybourne Capital Management (HK) Limited, Tybourne Strategic Opportunities GP II Limited, Tybourne Capital Management Limited, Tybourne Kesari Limited and Viswanathan Krishnan (collectively, the "Filers"). Each of the Filers may be required to file with the Unite |
|
| February 14, 2024 |
FBRX / Forte Biosciences, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d776810dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) C |
|
| February 14, 2024 |
FBRX / Forte Biosciences, Inc. / ALGER ASSOCIATES INC - FORTE BIOSCIENCES, INC. Passive Investment Forte Biosciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forte Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2024 |
FBRX / Forte Biosciences, Inc. / TYBOURNE CAPITAL MANAGEMENT (HK) LTD Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Forte Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2024 |
FBRX / Forte Biosciences, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
EX-99.1 2 d776810dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| January 11, 2024 |
EX-99.3 2 ex993.htm Please see pdf attached for document reference |
|
| January 11, 2024 |
^JCA> _NS;FNTW.H6Z@(T;=4'2C,*TQALK<9A3JF-8"JA M$\4*!^"!7(RS*0 [M@6@YR!J,[ begin 644 ex993.pdf M)5!$1BTQ+C8-)>+CS],-"C$Y,B P(&]B:@T\/"],:6YE87)I>F5D(#$O3" R M.#@W,SDO3R Q.30O12 Q,#(U-38O3B T,B]4(#(X.#$V.2]((%L@-#%LQ.3(@ M,C!=+TEN9F\@,3DQ(# @4B],96YG=&@@-C@O4')E=B R.#@Q-S O4F]O=" Q M.3,@,"!2+U-I>F4@,C$R+U1Y<&4O6%)E9B]76S$@,R Q73X^X7- MA)F'\1K#5Y4K#@8O)#QX==C6,[-.5'-;4)@F81P=#1(='0P=8-S @!=+L0,P-%CD*2A],<]F5 M&[email protected]%A;-K+N 0LV\C $BH*I!F!N!>(6QA84M9"^7\! @P ^ +/ M:0 |
|
| January 11, 2024 |
FBRX / Forte Biosciences, Inc. / BML Investment Partners, L.P. Activist Investment SC 13D/A 1 formsc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) Braden Leonard, BML Capital Management, LLC 65 E Cedar - Suite 2. Zionsville, IN 46077 Phon |
|
| January 9, 2024 |
SC 13D/A 1 ea191351-sc13da5funiforte.htm AMENDMENT NO. 5 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title |
|
| January 5, 2024 |
EX-99.3 2 ex99-3.htm Exhibit 99.3 |
|
| January 5, 2024 |
FBRX / Forte Biosciences, Inc. / Camac Fund, LP Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Amendment No 1. Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSI |
|
| December 8, 2023 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Inc |
|
| September 20, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 20, 2023 |
Amended and Restated 2021 Equity Incentive Plan Exhibit 10.1 FORTE BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Optio |
|
| September 15, 2023 |
FBRX / Forte Biosciences Inc / BML Investment Partners, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) Braden Leonard, BML Capital Management, LLC 65 E Cedar - Suite 2. Zionsville, IN 46077 Phone : 317-344-2447 (Name, A |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 12, 2023 |
FBRX / Forte Biosciences Inc / ALGER ASSOCIATES INC - FORTE BIOSCIENCES, INC. Passive Investment Forte Biosciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Forte Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109(CUSIP Number) August 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| September 8, 2023 |
FBRX / Forte Biosciences Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) July 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| September 8, 2023 |
Forte Biosciences, Inc. 24,856,250 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274257 PROSPECTUS Forte Biosciences, Inc. 24,856,250 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 24,856,250 shares (the “Shares”) of common stock, par value $0.001 per share, of Forte Biosciences, Inc., a Delaware corporation (the “Company”), by the selling stockholders ide |
|
| September 8, 2023 |
EX-99.1 2 d464766dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: September 8, 2 |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 6, 2023 |
September 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Daniel Crawford Re: Forte Biosciences, Inc. Registration Statement on Form S-3 File No. 333-274257 Acceleration Request Requested Date: September 8, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant |
|
| September 1, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 31, 2023 |
The Case for Boardroom Change at Forte Biosciences Prepared by Camac Partners and ATG Capital August 2023Concerned Stockholders of Forte Biosciences Legal Disclaimer The materials contained herein (the “Materials”) represent the opinions of Camac Fund, LP (together with its affiliates, “Camac”), ATG Capital Management, LLC (together with its affiliates, “ATG”) and the other participants named in the proxy solicitation (collectively, the “Group” or “we”) and are based on publicly available information with respect to Forte Biosciences, Inc. |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 29, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Forte Biosciences, Inc. |
|
| August 29, 2023 |
As filed with the Securities and Exchange Commission on August 29, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 29, 2023 Registration No. |
|
| August 29, 2023 |
CORRESP Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650. |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| August 24, 2023 |
DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 23, 2023 |
FBRX / Forte Biosciences Inc / Camac Fund, LP - THE SCHEDULE 13D Activist Investment SC 13D 1 sc13d1322400408222023.htm THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of |
|
| August 23, 2023 |
EX-99.1 2 ex991to13d1322400408222023.htm GROUP AGREEMENT Exhibit 99.1 GROUP AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Forte Biosciences, Inc., a Delaware corporation (the “Company”); WHEREAS, (i) Camac Fund, LP, Camac Partners, LLC, Camac Capital, LLC and Eric Shahinian (collectively, “Camac”), (ii) McIntyre Partnerships, LP, McIntyre Capital GP, LLC, |
|
| August 23, 2023 |
EX-99.2 3 ex992to13d1322400408222023.htm POWERS OF ATTORNEY Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Eric Shahinian the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Forte Bios |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid |
|
| August 15, 2023 |
FBRX / Forte Biosciences Inc / Wagner Paul A. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) Paul A. Wagner, Ph.D. Chief Executive Officer Forte Biosciences, Inc. 3060 Pegasus Park Dr. Building 6 Dall |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| August 10, 2023 |
FBRX / Forte Biosciences Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) J |
|
| August 10, 2023 |
FBRX / Forte Biosciences Inc / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 10, 2023 |
FBRX / Forte Biosciences Inc / ATG Fund II LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) Gabriel Gliksberg ATG Capital Management, LLC 805 N. Milwaukee Avenue, Suite 301 Chicago, IL 60642 (786) 519-0995 (N |
|
| August 10, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated August 10, 2023 with respect to the shares of Common Stock, $0.001 par value per share of Forte Biosciences, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accor |
|
| August 4, 2023 |
Exhibit 16.1 August 4, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Forte Biosciences, Inc.’s Form 8-K dated August 4, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4.01 |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)1 Forte Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) ERIC SHAHINIAN CAMAC PARTNERS, LLC 350 PAR |
|
| August 2, 2023 |
PREC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 1, 2023 |
EX-4.2 Exhibit 4.2 AMENDMENT NO. 2 TO PREFERRED STOCK RIGHTS AGREEMENT This AMENDMENT NO. 2 TO PREFERRED STOCK RIGHTS AGREEMENT (this “Amendment”) is dated as of July 28, 2023 (the “Effective Date”), and amends that certain Preferred Stock Rights Agreement, dated as of July 12, 2022, as amended by that certain Amendment No. 1 dated as of June 26, 2023 (the “Rights Agreement”), by and between Forte |
|
| August 1, 2023 |
Exhibit 99.2 FORTE BIOSCIENCES CORPORATE OVERVIEW CORPORATE PRESENTATION AUGUST 1, 2023 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation |
|
| August 1, 2023 |
Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES $25 MILLION FINANCING AND R&D UPDATE FOR FB-102 -FB-102 Has Demonstrated Potentially Best in Class Activity including Superiority to Standard of Care in GvHD -Proof of Concept Pre-clinical Data in Additional Indications with Large Market Potential Underscores Meaningful Opportunity -$25 Million Financing Highlights Significant Support from Top Tier In |
|
| August 1, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG FORTE BIOSCIENCES, INC., AND THE PURCHASERS JULY 28, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Common Stock 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 6 3.1 Organization and Power 6 3.2 Capitalization 6 3.3 Registration Rights 6 3.4 Authorization 7 3.5 Valid Issuance 7 3.6 No |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 1, 2023 |
Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of July 28, 2023 by and among Forte Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and the |
|
| August 1, 2023 |
Exhibit 4.1 THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES ARE BEING OFFERED TO INVESTORS WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT IN RELIANCE UPON REGULATION D PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE SECURITIES ACT”). TRANSFER OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON E |
|
| July 6, 2023 |
FBRX / Forte Biosciences Inc / Funicular Funds, LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34962G109 (CUSIP Number) Jacob Ma-Weaver Cable C |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 Forte Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) Eric Shahinian Camac Partners, LLC 350 Par |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1243872 (State of incorporation or organization) (I.R.S. Employer Identification No.) |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 26, 2023 |
EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO PREFERRED STOCK RIGHTS AGREEMENT This AMENDMENT NO. 1 TO PREFERRED STOCK RIGHTS AGREEMENT (this “Amendment”) is dated as of June 26, 2023 (the “Effective Date”), and amends that certain Preferred Stock Rights Agreement, dated as of July 12, 2022 (the “Rights Agreement”), by and between Forte Biosciences, Inc., a Delaware corporation (the “Company”), and Comput |
|
| May 25, 2023 |
Exhibit 99.1 JOINDER AGREEMENT This JOINDER AGREEMENT (the “Joinder”) is dated as of May 25, 2023, by and among Camac Fund, LP, Camac Partners, LLC, Camac Capital, LLC, Eric Shahinian, Michael G. Hacke and Chris McIntyre (collectively, the “Existing Members”), and McIntyre Partnerships, LP, McIntyre Capital GP, LLC, McIntyre Capital Management, LP and McIntyre Capital Management GP, LLC (collectiv |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Forte Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) ERIC SHAHINIAN CAMAC PARTNERS, LLC 350 PAR |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| April 10, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Forte Biosciences, Inc., a Delaware corporation. This |
|
| April 10, 2023 |
FBRX / Forte Biosciences Inc / JEC II Associates, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) March 30, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| March 31, 2023 |
EX-99.1 Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES FULL YEAR 2022 RESULTS AND PROVIDES BUSINESS UPDATE -FB-102 Continues to Advance Towards the Clinic DALLAS, TX – MARCH 31, 2023 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update. “FB-102 continues to pr |
|
| March 31, 2023 |
Forte Biosciences, Inc. 2021 Equity Incentive Plan. Exhibit 10.16 Appendix A 2021 Equity Incentive Plan FORTE BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan per |
|
| March 31, 2023 |
Power of Attorney (included on the signature page hereto). S-8 As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 sep For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38052 FORTE BIOSC |
|
| March 31, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Forte Biosciences, Inc. |
|
| March 31, 2023 |
Exhibit 21.1 Subsidiaries of Forte Biosciences, Inc.* Name of Subsidiary Jurisdiction of Incorporation or Organization Forte Subsidiary, Inc. Delaware Forte Biosciences Emerald Limited Ireland * Inclusion on the list above is not an admission that any of the above entities, individually or in the aggregate, constitutes a significant subsidiary within the meaning of Rule 1-02(w) of Regulation S-X a |
|
| March 31, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 29, 2023 |
FBRX / Forte Biosciences Inc / BML Investment Partners, L.P. - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) Braden Leonard, BML Capital Management, LLC 65 E Cedar - Suite 2. Zionsville, IN 46077 Phone : 317-344-2447 (Name, |
|
| February 21, 2023 |
Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Eric Shahinian the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Forte Biosciences, Inc., a Delaware corporation (the “Company”), direc |
|
| February 21, 2023 |
JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Forte Biosciences, Inc., a Delaware corporation (the “Company”); and WHEREAS, Camac Fund, LP, Camac Partners, LLC, Camac Capital, LLC and Eric Shahinian (collectively, “Camac”), Michael G. Hacke and Chris McIntyre (together with Mr. Hacke, the “Nominees”) wish to form |
|
| February 21, 2023 |
FBRX / Forte Biosciences Inc / Camac Fund, LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4) Under the Securities Exchange Act of 1934 Forte Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) Eric Shahinian Camac Partners, LLC 350 Park Avenue, 13th Floor New York, New York 10022 (914) 629-8496 (Name, Address and Telephone Number of Pe |
|
| February 9, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF FORTE BIOSCIENCES, INC. ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation’ |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 12, 2023 |
EX-99.1 Exhibit 99.1 MR. DAVID GRYSKA APPOINTED TO FORTE BIOSCIENCES BOARD OF DIRECTORS -Addition of Mr. David Gryska Further Strengthens Forte Board of Directors DALLAS, TX – JANUARY 12, 2023 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors. Mr. Gryska was previously the Chief Financ |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2022 |
Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalen |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| November 14, 2022 |
Exhibit 99.2 DR. SCOTT BRUN, M.D. APPOINTEED TO FORTE BIOSCIENCES BOARD OF DIRECTORS -Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors DALLAS, TX ? NOVEMBER 14, 2022 ? Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directo |
|
| November 14, 2022 |
Exhibit 10.1 FORTE BIOSCIENCES, Inc. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made between Forte Biosciences, Inc. (the ?Company?) and [] (the ?Executive?). This Agreement provides certain protections to the Executive in connection with the involuntary termination of the Executive?s employment under the circumstances described in |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 28, 2022 |
FBRX / Forte Biosciences Inc / Camac Fund, LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Forte Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) Eric Shahinian Camac Partners, LLC 350 Park Avenue, 13th Floor New York, NY 10022 914-629-8496 (Name, Address and Telephone Number of Person Aut |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34962G109 (CUSIP Number) Jacob Ma-Weaver Cable C |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 2)1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34962G109 (CUSIP Number) Jacob Ma-Weaver Cable C |
|
| August 24, 2022 |
Exhibit 99.1 Funicular Funds, LP 2261 Market Street #4307 San Francisco, California 94114 Forte Biosciences, Inc. 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 August 24, 2022 Dear Members of the Board of Directors: As the Company’s largest stockholder, with beneficial ownership of approximately of 9.9% of the shares of common stock outstanding of Forte Biosciences, Inc. (“Forte” or the |
|
| August 18, 2022 |
Exhibit 99.2 Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise Fears the Board has Diluted Shareholders for Self-Serving Purposes Following the Emergence of Four 13D Filers, Suggesting the Directors Have Potentially Breached Their Fiduciary Duties Notes the Company Trades at a ~40% Discount to Cash Urges the Board to Reverse Course and Return Capital to |
|
| August 18, 2022 |
FBRX / Forte Biosciences Inc / Camac Fund, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Forte Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) ERIC SHAHINIAN CAMAC PARTNERS, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK, NY 10022 914-629-8496 (Name, Address and Telephone Number of Person Aut |
|
| August 16, 2022 |
FBRX / Forte Biosciences Inc / BML Investment Partners, L.P. - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) Braden Leonard, BML Capital Management, LLC 65 E Cedar - Suite 2. Zionsville, IN 46077 Phone : 317-344-2447 (Name, |
|
| August 15, 2022 |
Exhibit 10.1 3060 Pegasus Park Drive Building 6 Dallas, Texas 75247 May 31, 2022 Hubert Chen, M.D. Via Email - [email protected] Dear Dr. Chen: I am pleased to provide this offer for you to serve Forte Biosciences, Inc. (the ?Company?) as its President and Chief Scientific Officer, reporting to the Chief Executive Officer. If you decide to accept this offer, the terms of this offer will be eff |
|
| August 15, 2022 |
Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -Forte Biosciences is Developing a Novel Pipeline for the Treatment of Autoimmune Diseases- -Leadership Strengthened with Appointments of Hubert Chen, M.D. as Chief Scientific Officer and Stephen Doberstein, Ph.D. to the Board of Directors- -Ended second quarter 2022 with approximately $38.5 mil |
|
| August 15, 2022 |
Exhibit 10.2 Forte Biosciences, Inc. Amended and Restated Non-Employee Director Compensation Policy (February 23, 2022) Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Forte Biosciences, Inc. (?Forte Biosciences?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Amend |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| August 15, 2022 |
Forte biosciences Developing treatments for Autoimmune diseases Corporate PRESENTATION AUGUST 2022 Exhibit 99. |
|
| August 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2022 |
FORTE BIOSCIENCES, INC. $2,700,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256611 PROSPECTUS SUPPLEMENT (To Prospectus dated June 7, 2021) FORTE BIOSCIENCES, INC. $2,700,000 Common Stock We have entered into an At Market Issuance Sales Agreement, or the sales agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg, relating to shares of our common stock, $0.001 par value per share, offered by thi |
|
| August 9, 2022 |
FBRX / Forte Biosciences Inc / Camac Fund, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Forte Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) ERIC SHAHINIAN CAMAC PARTNERS, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK, NY 10022 914-629-8496 (Name, Address and Telephone Number of Person Au |
|
| August 4, 2022 |
FBRX / Forte Biosciences Inc / ATG Fund II LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) Gabriel Gliksberg ATG Capital Management, LLC 805 N. Milwaukee Avenue, Suite 301 Chicago, IL 60642 (786) 519-0995 (Na |
|
| August 4, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons and entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock, par value $0. |
|
| August 4, 2022 |
Transactions in the Common Stock. Exhibit 2 Transactions in the Common Stock The following table sets forth all transactions in the Common Stock effected during the past sixty (60) days by any of the Reporting Persons, all of which were open market purchases of shares of Common Stock by ATG Fund II LLC: Date of Transaction Number of Shares Purchased Price Per Share 6/9/2022 87 $1. |
|
| August 1, 2022 |
FBRX / Forte Biosciences Inc / Camac Fund, LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Forte Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) ERIC SHAHINIAN CAMAC PARTNERS, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK, NY 10022 914-629-8496 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| August 1, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT This JOINT FILING AGREEMENT is entered into as of December 30, 2019, by and among the signatories hereto. The undersigned hereby agree that the Statement on Schedule 13D with respect to the shares of Common Stock of Forte Biosciences, Inc., and any amendment thereafter signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to an |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34962G109 (CUSIP Number) Jacob Ma-Weaver Cable C |
|
| July 12, 2022 |
8-A12B 1 d654017d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1243872 (State of incorporation or organization) (I.R.S. Employer Identi |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 (July 11, 2022) Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38052 26-1243872 (State or other jurisdiction of incorporatio |
|
| July 12, 2022 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A PARTICIPATING PREFERRED STOCK OF FORTE BIOSCIENCES, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware Forte Biosciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), in accordance with the provision |
|
| July 12, 2022 |
Exhibit 4.1 PREFERRED STOCK RIGHTS AGREEMENT Dated as of July 12, 2022 between FORTE BIOSCIENCES, INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 12 Section 3. Issuance of Rights Certificates 12 Section 4. Form of Rights Certificates 14 Section 5. Countersignature and Registration 15 Section |
|
| July 7, 2022 |
FBRX / Forte Biosciences Inc / BML Investment Partners, L.P. - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) Braden Leonard, BML Capital Management, LLC 65 E Cedar - Suite 2. Zionsville, IN 46077 Phone : 317-344-2447 (Name, |
|
| July 5, 2022 |
FBRX / Forte Biosciences Inc / Funicular Fund, LP - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34962G109 (CUSIP Number) Jacob Ma-Weaver Cable Ca |
|
| June 24, 2022 |
EX-FILING FEES 4 d369162dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate |
|
| June 24, 2022 |
As filed with the Securities and Exchange Commission on June 24, 2022 As filed with the Securities and Exchange Commission on June 24, 2022 Registration No. |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 7, 2022 |
Exhibit 99.1 Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President DALLAS?(BUSINESS WIRE)? Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer and President. ?Dr. Chen is a very accompl |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 24, 2022 |
FBRX / Forte Biosciences Inc / BML Investment Partners, L.P. - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) Braden Leonard, BML Capital Management, LLC 65 E Cedar - Suite 2. Zionsville, IN 46077 Phone : 317-344-2447 (Name |
|
| May 19, 2022 |
DEFA14A 1 d349253ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| May 16, 2022 |
Exhibit 99.1 FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -Forte Biosciences to Develop Novel Pipeline for the Treatment of Autoimmune Diseases- -Leadership Strengthened with Appointments of Stephen Doberstein, Ph.D. and Barbara Finck, M.D.to the Board of Directors- -Ended first quarter 2022 with approximately $40.0 million in cash and cash equivalents- |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 12, 2022 Date of Report (Date of earliest event reported) Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38052 26-1243872 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 16, 2022 |
Forte biosciences Developing treatments for Autoimmune diseases Corporate PRESENTATION May 2022 Exhibit 99. |
|
| May 4, 2022 |
FBRX / Forte Biosciences Inc / BML Investment Partners, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34962G109 (CUSIP Number) April 26, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 1, 2022 |
Exhibit 10.1 Forte Biosciences, Inc. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement March 31, 2022 Ladenburg Thalmann & Co. Inc. 640 5th Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Forte Biosciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Ladenburg Thalmann & Co. Inc. (the ?Agent?) as follows: 1. Iss |
|
| April 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2022 Date of Report (Date of earliest event reported) Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38052 26-1243872 (State or other jurisdiction of incorporation) (Commission F |
|
| April 1, 2022 |
FORTE BIOSCIENCES, INC. $7,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256611 PROSPECTUS SUPPLEMENT (To Prospectus dated June 7, 2021) FORTE BIOSCIENCES, INC. $7,000,000 Common Stock We have entered into an At Market Issuance Sales Agreement, or the sales agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg, relating to shares of our common stock, $0.001 par value per share, offered by thi |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 sep For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38052 FORTE BIOSC |
|
| March 31, 2022 |
Exhibit 10.32 Appendix A 2021 Equity Incentive Plan FORTE BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan per |
|
| March 31, 2022 |
Exhibit 21.1 Subsidiaries of Forte Biosciences, Inc.* Name of Subsidiary Jurisdiction of Incorporation or Organization Forte Subsidiary, Inc. Delaware Forte Biosciences Emerald Limited Ireland * Inclusion on the list above is not an admission that any of the above entities, individually or in the aggregate, constitutes a significant subsidiary within the meaning of Rule 1-02(w) of Regulation S-X a |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 16, 2022 Date of Report (Date of earliest event reported) Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38052 26-1243872 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* (Name of Issuer) Forte Biosciences, Inc. (Title of Class of Securities) Common Stock, $0.001 Par Value |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
FBRX / Forte Biosciences Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34963G 109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) |
|
| February 11, 2022 |
CUSIP No. 34962G109 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, par value $0.0001 per share, of Forte Biosciences, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the S |
|
| February 11, 2022 |
FBRX / Forte Biosciences Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. |
|
| February 3, 2022 |
FBRX / Forte Biosciences Inc / FRANKLIN RESOURCES INC Passive Investment fort21a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 34962G109 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* FORTE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 34962G109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fi |
|
| February 2, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 1, 2022 Date of Report (Date of earliest event reported) Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38052 26-1243872 (State or other jurisdiction of incorporation) (Commission |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| October 13, 2021 |
FBRX / Forte Biosciences Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 21, 2021 |
FBRX / Forte Biosciences Inc / Oliveira Steven Michael - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2)* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34962G109 (CUSIP Number) September 7, |
|
| September 16, 2021 |
FBRX / Forte Biosciences Inc / Wagner Paul A. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forte Biosciences, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 34962G109 (CUSIP Number) Paul A. Wagner, Ph.D. President and Chief Executive Officer Forte Biosciences, Inc. 1124 W Carson Street MRL |
|
| September 13, 2021 |
FBRX / Forte Biosciences Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Forte Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34962G109 (CUSIP Number) September 2, 20211 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| September 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 2, 2021 Date of Report (Date of earliest event reported) Forte Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38052 26-1243872 (State or other jurisdiction of incorporation) (Commissio |
|
| September 2, 2021 |
Exhibit 99.1 CLINICAL TRIAL OF FB-401 FOR THE TREATMENT OF ATOPIC DERMATITIS FAILS TO MEET STATISTICAL SIGNIFICANCE TORRANCE, CA ? SEPTEMBER 2, 2021 ? Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical si |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 FORTE BIOSCIENCES, INC. |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission Fi |
